Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AurKA shRNA
- Development stage
- Preclinical
- Lead developer
- The Ohio State University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intraperitoneal, Parenteral
01
Overview
AurKA shRNA is a short hairpin RNA (shRNA) designed to silence the expression of Aurora Kinase A (AurKA), a serine/threonine kinase that plays a critical role in mitotic spindle assembly and cell cycle regulation. AurKA is frequently overexpressed in various cancers, including glioblastoma, breast, and lung cancers, where it contributes to oncogenic transformation and aneuploidy. By utilizing RNA interference (RNAi) to knockdown AurKA levels, this agent prevents cells from prematurely surpassing the G2/M checkpoint, thereby sensitizing them to radiation therapy. Research conducted at the Ohio State University-Comprehensive Cancer Center has demonstrated that lentiviral-mediated delivery of AurKA shRNA in glioblastoma cell lines leads to reduced proliferation, increased apoptosis, and the prevention of polyploid cell accumulation following radiation treatment.
- Other names
- Aurora kinase A shRNAAURKA shRNAAurKA short hairpin RNA
02
Targets
AURKA (Aurora kinase A)
Beyond the preview
Go deeper on AurKA shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AurKA shRNA.